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Chertsey, UKAbstractClostridium difﬁcile infection remains a major healthcare burden. Until the recent introduction of ﬁdaxomicin, antimicrobial treatments were
limited to metronidazole and vancomycin. The emergence of epidemic C. difﬁcile PCR ribotype 027 and its potential link to decreased
antibiotic susceptibility highlight the lack of large-scale antimicrobial susceptibility and epidemiological data available. We report results of
epidemiological and antimicrobial susceptibility investigations of C. difﬁcile isolates collected prior to ﬁdaxomicin introduction, establishing
important baseline data. Thirty-nine sites in 22 countries submitted a total of 953 C. difﬁcile isolates for PCR ribotyping, toxin testing, and
susceptibility testing to metronidazole, vancomycin, ﬁdaxomicin, rifampicin, moxiﬂoxacin, clindamycin, imipenem, chloramphenicol, and
tigecycline. Ninety-nine known ribotypes were identiﬁed. Ribotypes 027, 014, 001/072, and 078 were most frequently isolated in line
with previous European studies. There was no evidence of resistance to ﬁdaxomicin, and reduced susceptibility to metronidazole and
vancomycin was also scarce. Rifampicin, moxiﬂoxacin, and clindamycin resistance (13%, 40%, and 50% of total isolates, respectively) were
evident in multiple ribotypes. There was a signiﬁcant correlation between lack of ribotype diversity and greater antimicrobial resistance
(measured by cumulative resistance score). Well-known epidemic ribotypes 027 and 001/072 were associated with multiple antimicrobial
resistance, but high levels of resistance were also observed, particularly in 018 and closely related emergent ribotype 356 in Italy. This
raises the possibility of antimicrobial exposure as the underlying reason for their appearance, and highlights the need for ongoing
epidemiological and antimicrobial resistance surveillance.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: jane.freeman4@nhs.netIntroductionClostridium difﬁcile infection (CDI) is a major concern in
healthcare environments, notably associated with excess mor-
tality [1]. CDI represents a signiﬁcant burden upon healthcareMicrobiol Infect 2015; 21: 248.e9–248.e16
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.09.017and ﬁnancial resources. Metronidazole and vancomycin have
been the main treatment options for CDI, but high recurrence
rates and reports of reduced metronidazole susceptibility
among epidemic C. difﬁcile ribotypes have highlighted the need
for new agents (https://www.gov.uk/government/uploads/
system/uploads/attachment_data/ﬁle/347169/CDRN_annual_
report.pdf) [2,3]. Fidaxomicin is a new macrocyclic antimicro-
bial with potent anti-C. difﬁcile activity, that is non-inferior to
vancomycin, with lower rates of CDI recurrence and minimal
gut ﬂora disruption [4]. Marketing authorisation for ﬁdaxomicin
in 2012 included a commitment to undertake antimicrobialious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Freeman et al. Antibiotic resistance among prevalent Clostridium difﬁcile ribotypes 248.e10resistance surveillance pre- and post-introduction. This affords
a welcome opportunity to gather valuable antimicrobial sus-
ceptibility, epidemiological, and demographic data across
Europe, and so ﬁll a gap in the identiﬁcation of local, national,
and international epidemiological resistance trends.
The ClosER (Clostridium difﬁcile European Resistance) study
aims to: identify and monitor the longitudinal susceptibility of
contemporaneous C. difﬁcile clinical isolates to antibiotics used
for CDI treatment and those previously implicated in selection
pressure; establish a comprehensive susceptibility database
baseline for on-going surveillance; and provide data on the
geographical distribution of clinical C. difﬁcile strain types with
analysis by region across Europe. We present here epidemio-
logical and antimicrobial susceptibility data for C. difﬁcile isolates
collected prior to the introduction of ﬁdaxomicin.MethodsStudy design
ClosER is a 3-year pan-European, multi-centre in vitro surveil-
lance study. The study period includes surveillance for 1 year
prior to the introduction of ﬁdaxomicin to the European
market (July 2011– June 2012). Data will subsequently be
available for 2 years post-introduction (2012–2014).
Participating centres were mainly national or regional C. difﬁcile
referral laboratories, selected using the European Study Group on
Clostridium difﬁcile (ESGCD) network (ECDIS-net), and with
ESGCD approval. The number of sites approached per country
was based on population (one site per 15 million population) or
reported incidence of CDI (at least two sites for countries with
>20 cases per 10,000 patient days per hospital), as in the study by
Bauer et al. [5]. Sites were recruited on the basis that they:
1) were actively sampling and testing for CDI
2) experienced sufﬁcient numbers of clinical CDI cases in
order to reach a target of 25 de-duplicated cases during
the 6-month collecting period
3) were willing to submit the required number of samples
over 3 years
Fifty-one participating sites from 28 European countries
were recruited and asked to submit 25 C. difﬁcile isolates or
toxin-positive faecal samples from de-duplicated CDI cases
during each year. No further stipulations were made.
Isolates or faecal samples were submitted to a central lab-
oratory (Leeds, UK) for PCR ribotyping, determination of toxin
status, and susceptibility to metronidazole, vancomycin, rifam-
picin, ﬁdaxomicin, moxiﬂoxacin, clindamycin, chloramphenicol
and tigecycline.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfResults were communicated back to the participating labo-
ratories in full.
Culture and toxin testing
Alcohol-shocked faecal specimens/C. difﬁcile isolates were
inoculated on to cycloserine-cefoxitin-egg-yolk agar (LabM,
Heywood, Lancashire, UK) with lysozyme and cultured anaer-
obically for 48 hours at 37°C. Forty-eight-hour anaerobic brain-
heart infusion broth culture supernatants of each test isolate
were added to a Vero cell culture cytotoxicity assay with
Clostridium sordellii antitoxin (ProLab Diagnostics, Brom-
borough, Merseyside, UK) neutralization.
Ribotyping
PCR ribotyping was performed on each isolate by the Clos-
tridium difﬁcile Ribotyping Network Reference Laboratory at
Leeds Teaching Hospitals Trust, Leeds, UK (according to
Stubbs et al. using capillary electrophoresis) [6,7]. Ribotypes
were assigned against the Cardiff Anaerobe Reference Unit
reference library at Leeds.
Susceptibility testing
Susceptibility of isolates (minimum inhibitory concentrations
(MICs)) to metronidazole, vancomycin, rifampicin, chloram-
phenicol (Sigma, Dorset, UK); moxiﬂoxacin (Bayer, Leverkusen,
Germany); clindamycin, tigecycline (Pﬁzer, New York, NY);
imipenem (MSD, Hertfordshire, UK); and ﬁdaxomicin (Astellas,
Chertsey, Surrey, UK) were determined by a Wilkins Chalgren
agar incorporation method as previously described [2].
Breakpoints are deﬁned in Table 1.ResultsThirty-nine of the recruited 51 European sites submitted a total
of 953 isolates or faecal samples collected during Year 1. Thirty-
three (3.5%) submissions did not yield C. difﬁcile; 91% of sub-
missions yielded a toxigenic C. difﬁcile isolate (n = 866).
PCR ribotyping results
Ninety-nine known ribotypes (RT) and 12 previously unseen
proﬁles were observed. The most common RTs encountered
were RTs 027 (12%), 001/072 (9%), 078, and 014 (both 8%)
(Fig. 1). RT prevalence differed markedly according to country,
with some exhibiting predominant RTs, while others showed a
wide diversity of types.
Antimicrobial susceptibility (Tables, 1, 2 and 3)
All isolates were susceptible to ﬁdaxomicin, with MIC50 and
MIC90 well below the epidemiological cut-off value (http://ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 248.e9–248.e16
TABLE 1. Susceptibility of all Clostridium difﬁcile isolates to 9 antimicrobials
Metronidazole Vancomycin Fidaxomicin Rifampicin Moxiﬂoxacin Clindamycin Imipenem Chloramphenicol Tigecycline
n = 916 918 918 918 918 917 918 919 919
Range  0.125–8  0.125–16  0.002–0.25  0.001–>16 0.125–>64 0.125–>64 0.125–>64  2–256 0.03–1
MIC50 (mg/L) 0.25 1 0.06 0.002 2 4 4 8 0.06
MIC90 (mg/L) 2 2 0.125 >16 32 >64 8 8 0.06
% S (breakpoint
mg/L)
97.82 ( 2) 96.84 ( 2) 100 (< 1) 79.41 ( 0.004) 58.17 ( 2) 37.62 ( 2) 61.98 ( 4) 93.14 ( 8) 99.56 (< 0.25)
% I (breakpoint
mg/L)
2.07 (4) 2.29 (4) 0$ (>1) 19.61 (0.004–16) 1.85 (4) 12.76 (4) 30.61 (8) 3.16 (16) 0.44$ (>0.25)
% R (breakpoint) 0.11 ( 8) 0.87 ( 8) – 13.40 ( 16) 39.99 ( 8) 49.62 ( 8) 7.41 ( 16) 3.70 ( 32) –
CLSI, U.S. Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration.
Breakpoints were deﬁned as as sensitive (S), intermediately resistant (I) or resistant (R) with reference to CLSI, EUCAST or published data (see Table 2). For tigecycline and
ﬁdaxomicin, MICs were compared to the EUCAST epidemiological cut-off value (1 mg/L) (7) and deﬁned as sensitive or reduced susceptibility.
248.e11 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIwww.ema.europa.eu/docs/en_GB/document_library/EPAR_-_
Public_assessment_report/human/002087/WC500119707.pdf)
(Table 1). Metronidazole, vancomycin, and tigecycline were
active against 97.82%, 96.84%, and 99.56% of isolates tested,
respectively; only a single UK isolate (RT106) had a metroni-
dazole MIC of 8 mg/L. Twenty isolates showed reduced
metronidazole susceptibility (from Czech Republic, Denmark,
Germany, Italy, Hungary, Poland, Switzerland, and UK), 11 of
which were RT027. Geometric mean metronidazole MICs
were elevated in RT027 (1.42 mg/L), RT106, RT001/072 (both
0.65 mg/L), and RT356 (0.61mg/L) isolates compared with a
range of 0.13–0.41 mg/L for the remaining prevalent RTs.
Reduced vancomycin susceptibility was rare (94–100% sensi-
tivity) in the 20 most prevalent RTs. Czech Republic, Ireland,
Latvia, and Poland submitted single isolates with vancomycin%7.07
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Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectMICs of 4 mg/L. Italy and Spain submitted multiple RTs dis-
playing reduced vancomycin susceptibility, including resistant
RT027, RT126, RT356, and RT001/072 isolates (>8 mg/L).
Vancomycin MICs were notably higher among ribotypes 018
and 356, with geometric mean MICs of 2.00 and 2.28 mg/L,
respectively, compared with a range of 0.62–0.95 mg/L for the
remaining common RTs.
Rifampicin resistance (13.4%) was observed in submissions
from 17/22 countries and in multiple RTs. In Italy, only 37.63%
of isolates were rifampicin susceptible. All RT018 and 356
isolates (the predominating clones from Italy) were either
intermediately or fully resistant to rifampicin. Czech Republic,
Denmark, and Hungary also showed high levels of resistant
isolates (63.64%, 56.52%, and 58.67% of total isolates, Table 3).
In Denmark and Hungary, rifampicin resistance was almost%54
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CMI Freeman et al. Antibiotic resistance among prevalent Clostridium difﬁcile ribotypes 248.e12
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infexclusively associated with predominating RT027, but was
evident in multiple RTs (017, 027, 176, and 001/072) in Czech
Republic.
Moxiﬂoxacin (39.99%) and clindamycin (49.62%) resistance
were common and present in all participating countries. Rates
of moxiﬂoxacin resistance (intermediate or full) varied
considerably from 8.00% in France to 100% in Poland (Table 3).
Moxiﬂoxacin resistance rates varied across the most common
RTs. RT356 was uniformly moxiﬂoxacin resistant (geometric
mean MIC = 50.80 mg/L); RTs 018, 027, and 017 also had
elevated geometric mean MICs (35.33, 22.28, and 18.22 mg/L,
respectively). Clindamycin resistance was seen in all the most
common RTs, but most notable among RT001/072, RT012,
RT017, RT046, and RT126.
Most isolates were sensitive to imipenem (61.98%). Geo-
metric mean imipenem MICs were highest in RT027 and RT106
(7.12 and 6.54 mg/L, respectively). Intermediate resistance
(30.6%) was present in all the common RTs. Most prevalent
RTs were largely susceptible (95–100% of isolates) to chlor-
amphenicol, with geometric mean MICs between 4.87 and
9.7 mg/L), but resistance was notable among RT001/072 iso-
lates from Latvia.
Antimicrobial susceptibility according to country
(Fig. 2)
MIC results for each isolate were designated susceptible (S),
intermediately resistant (I), or fully resistant (R) according to
breakpoints (Table 1); each result was assigned a score (S = 0;
I = 1, and R = 2). A cumulative resistance score based on
susceptibility to each of the nine antimicrobials tested was then
generated for each isolate. Thus, an isolate that was fully sus-
ceptible to four, intermediately resistant to two, and resistant
to three antimicrobials would generate a score of 8
(0 + 0 + 0 + 0 + 1 + 1 + 2 + 2 + 2). Isolates were then grouped
according to country, and mean cumulative resistance scores
were generated for each country.DiscussionEpidemiological surveillance of ribotypes
This is the largest pan-European study to date of C. difﬁcile RT
and antibiotic susceptibility epidemiology. Surveillance of more
than 900 isolates submitted by 39 sites across 22 European
countries showed a diverse array of known RTs across Europe
(n = 99), with 12 previously unreported RTs. The most
commonly isolated RTs (Fig. 1) were broadly similar to those
reported by Bauer et al., who examined 389 C. difﬁcile isolates
from across Europe [5]. Previously described epidemic or
highly prevalent types (014/20, 027, 001/072, and 078)ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 248.e9–248.e16
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<1
1-2
2-3
3-4
4-5
5-6
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FIG. 2. Distribution of cumulative antimicrobial resistance in Clostridium difﬁcile in 22 European countries (% of resistant C. difﬁcile isolates per
antibiotic).
248.e13 Clinical Microbiology and Infection, Volume 21 Number 3, March 2015 CMIremained prevalent in this study, but inter-country variations in
relative prevalence of particular strains were apparent. This is
not unexpected, since both endemic and epidemic spread of
C. difﬁcile is well documented [5,8–11]. Changes in RT meth-
odology have led to greater discriminatory power and subdi-
vision of types; the present study divides RT014/020 (16%
prevalence in an earlier study) into two distinct RTs: 014 and
020 (8.1% and 4.2%, respectively) [5].
RT005, RT087, and RT356 were more prevalent than pre-
viously observed [5]. RT005 and RT087 were among the most
antibiotic susceptible of the commonly isolated RTs. Con-
trastingly, RT356 isolates were submitted only from Italy and
were among the least antibiotic susceptible of the whole
cohort. RT018 accounted for >20% of Italian isolates in this
study. The emergence of this type in Italy is documented [11],
but RT356 has not been reported previously. Interestingly, the
PCR banding proﬁles of RT018 and RT356 are closely related
(94% similarity) and may belong to the same multi-locus
sequence (MLST) type (Dr. Warren Fawley, personal commu-
nication). RT018 was detected ﬁrst, indicated by its lower type
number and earlier literature citation [11]. Taken together, it is
possible that RT356 strains may have evolved from the RT018
lineage. Genome sequencing of these isolates is underway and
will potentially add further clarity regarding both strain prov-
enance and resistance development [12].
Antimicrobial susceptibility surveillance
There was no evidence of reduced susceptibility to ﬁdaxomicin,
consistent with earlier studies that reported good activityClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect(range 0.006–1 mg/L) [13–18]. Finegold et al. reported a single
isolate with a ﬁdaxomicin MIC of 2 mg/L [16]. It has been re-
ported that ‘hypervirulent’ C. difﬁcile strains (including RT027)
may be less ﬁdaxomicin susceptible than others [13,18]. We
observed no clear differences in susceptibility among RTs
(geometric mean MICs ranged from 0.01–0.07 mg/L), despite
the isolates originating from similar places as in the study by
Debast et al [18].
These data represent a baseline for future studies of C. difﬁcile
after the introduction of ﬁdaxomicin. Goldstein et al. reported a
C. difﬁcile strain with a ﬁdaxomicin MIC of 16 mg/L isolated from
a patient with recurrent diarrhoea 6 days after the last antibiotic
dose [13]. The relatedness of the pre- and post-treatment strains
was not determined, and the association of resistance with drug
exposure cannot be made deﬁnitively. The clinical signiﬁcance of
such a strain is unclear, given that ﬁdaxomicin achieves faecal
concentrations in excess of 1000 ug/g [13]. Reduced metroni-
dazole susceptibility was uncommon in our study, but most
evident among RT027 and RT106 (geometric mean MIC = 1.42
and 0.65 mg/L, respectively), as previously described (https://
www.gov.uk/government/uploads/system/uploads/attachment_
data/ﬁle/347169/CDRN_annual_report.pdf) [2], and in emergent
RT018 and RT356 (geometric means 0.41 and 0.61 mg/L,
respectively). Single vancomycin-resistant strains of prevalent
RTs were found: 014, 027, 078, 126, 001/072, and three among
the emergent RT356 strains. One RT356 isolate had a vanco-
mycin MIC of 16 mg/L; again, the clinical signiﬁcance of elevated
vancomycin MICs is unclear in the light of high gut vancomycin
concentrations in vivo [19].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 248.e9–248.e16
TABLE 3. Percentage of Clostridium difﬁcile isolates showing intermediate or full resistance to 9 antimicrobials by country
n Metronidazole Vancomycin Fidaxomicin Rifampicin Moxiﬂoxacin Clindamycin Imipenem Chloramphenicol Tigecycline
Austria 25 0.00 0.00 0.00 0.00 28.00 28.00 16.00 4.00 4.00
Belgium 25 0.00 0.00 0.00 4.00 12.00 56.00 0.00 0.00 0.00
Bulgaria 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cyprus 16 0.00 0.00 0.00 25.00 68.75 100.00 37.50 0.00 0.00
Czech Rep 22 4.55 4.55 0.00 63.64 77.27 63.64 40.91 18.18 0.00
Denmark 23 8.70 4.35 0.00 56.52 43.48 73.91 39.13 4.35 0.00
France 50 0.00 0.00 0.00 0.00 8.00 58.00 40.00 2.00 0.00
Germany 52 3.85 0.00 0.00 40.38 48.08 36.54 28.85 17.31 0.00
Greece 50 0.00 0.00 0.00 8.00 38.00 70.00 60.00 6.00 0.00
Hungary 75 2.67 0.00 0.00 58.67 77.33 28.00 76.00 1.33 0.00
Ireland 50 0.00 2.00 0.00 0.00 10.00 88.00 40.00 0.00 0.00
Italy 93 3.23 15.05 0.00 62.37 78.49 56.99 43.01 1.08 0.00
Latvia 25 0.00 4.00 0.00 4.00 88.00 76.00 72.00 68.00 0.00
Poland 20 40.00 5.00 0.00 5.00 100.00 100.00 55.00 15.00 0.00
Portugal 24 0.00 0.00 0.00 8.33 20.83 45.83 16.67 0.00 0.00
Slovakia 25 0.00 0.00 0.00 4.00 72.00 100.00 36.00 8.00 8.00
Slovenia 25 0.00 0.00 0.00 0.00 20.00 100.00 12.00 0.00 4.00
Spain 75 0.00 12.00 0.00 13.33 42.67 34.67 29.33 9.33 4.00
Sweden 25 0.00 0.00 0.00 4.00 20.00 20.00 0.00 4.00 0.00
Switzerland 39 2.56 0.00 0.00 2.56 23.08 76.92 23.08 2.56 0.00
The Netherlands 25 0.00 0.00 0.00 4.00 40.00 92.00 12.00 20.00 0.00
UK 147 0.68 0.00 0.00 0.68 18.37 72.79 38.10 0.68 0.00
CMI Freeman et al. Antibiotic resistance among prevalent Clostridium difﬁcile ribotypes 248.e14Rifampicin resistance was relatively common (15 of 22
countries), but was most prevalent in Czech Republic,
Denmark, Hungary, and Italy (56.52–63.64%) (Fig. 2). Rifam-
picin resistance was relatively common in prevalent RTs in
some settings; for example, RT027, RT018, and RT356 in
Denmark, Hungary, and Italy, respectively. Prevalent RTs
exhibited rifampicin resistance related to speciﬁc locales; e.g.
rifampicin resistance was prevalent in RT001/072 isolates from
the Czech Republic, but not in those from Germany, Latvia, and
Slovakia. Intermediate rifampicin resistance was found in Italian
RT027 isolates, but not in those from Poland.
All RT018 and RT356 isolates from Italy were intermediately
or fully rifampicin resistant. Interestingly, the two RT018 isolates
from outside of Italy were considerably more susceptible to
rifampicin (MIC 0.002 mg/L) than the Italian RT018 isolates.
Notably, the other prevalent clone in Italy, RT027, showed in-
termediate resistance to rifampicin (geometric mean 1 mg/L).
Goldstein et al. described markedly higher rifampicin MICs
among C. difﬁcile isolates from Italy (geometric mean
MIC = 8.3 mg/L, MIC50 and MIC90 >256 mg/L) than most other
countries [13]. Miller et al. found eightfold higher rifaximin
resistance in isolates from Italy than those from Canada. They
commented that rifaximin has been in use for over 2 decades in
Italy, but remains unlicensed in Canada [20], highlighting the
possibility of selection for rifamycin resistance secondary to drug
exposure. Associations between rifamycin exposure and selec-
tion of resistant C. difﬁcile were also made by Curry et al. and
O’Connor et al. [21,22]. Obuch-Woszczatynski et al. described
emergence of rifampicin resistance in RT046 isolates from pa-
tients on long-term rifampicin treatment for tuberculosis [23].
Using WHO data we note that there is a (non-signiﬁcant, p,
0.07) correlation between locations harbouring increased
rifampicin resistance in tuberculosis of native origin and ClosERClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infstudy countries showing increased rifampicin resistance in
C. difﬁcile [24]. It is interesting also that contemporaneous data
show that Staphylococcus aureus rifampicin resistance in Europe is
most prevalent in Italy (14.8%) (http://www.ecdc.europa.eu/en/
healthtopics/antimicrobial_resistance/database/Pages/table_
reports.aspxf). Thus, there is circumstantial evidence to support
the selection and emergence of rifampicin-resistant isolates in
Italy. Whole genome sequencing of our study isolates will be
helpful to determine the evidence for clonality of RT356 strains.
The present study conﬁrmed previously reported associa-
tions between prevalent types, such as RT027 and RT001/072,
and resistance to moxiﬂoxacin, clindamycin, and chloram-
phenicol [8,11,15,25]. Clusters of chloramphenicol-resistant
001/072 isolates were found in Germany, The Netherlands,
and Latvia. Contrastingly, in Slovakia, from which 72% of sub-
missions were RT001/072, resistance was observed in only two
isolates. This may indicate local expansion of chloramphenicol-
resistant strains following acquisition of mobile resistance de-
terminants [26].
Imipenem resistance is not well documented in C. difﬁcile, but
we found evidence of intermediate and full resistance (38%).
Geometric mean imipenem MICs were highest among RT027
(7.12 mg/L), but high-level resistance (>64 mg/L) was observed
in single RT014 and RT050 isolates from the same institution.
Higher rates of imipenem resistance among human vs. animal
C. difﬁcile isolates (55.6 vs. 28.1%) were attributed to absent
veterinary carbapenem use in one study [27]. Our data suggest
that resistance to imipenem in C. difﬁcile could be emerging as a
result of carbapenem prescribing.
There was a signiﬁcant inverse correlation between number
of RTs identiﬁed in a locality and mean cumulative resistance
score (Pearson correlation efﬁcient, r = −0.64; p=0.0017),
indicating lower antimicrobial resistance levels amongectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 248.e9–248.e16
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Northern and Western Europe) (Fig. 2). This may be due to
the introduction of mandatory reporting programmes, with
consequent increase in awareness, antimicrobial stewardship,
and infection control interventions driving down the rates of
endemic RTs. There are few published data describing the
epidemiology and antimicrobial susceptibility of circulating RTs
across Europe. The emergence of hypervirulent RT027 in the
early 2000s had a signiﬁcant impact upon healthcare systems
[28]. The rapid emergence of RT027, and recent reports of
reduced metronidazole susceptibility (https://www.gov.uk/
government/uploads/system/uploads/attachment_data/ﬁle/
347169/CDRN_annual_report.pdf) [2] highlight the need for
large-scale surveillance schemes to identify emerging RTs and
potential resistance development. To date, surveillance
schemes have tended to be local or national, rather than in-
ternational, in scope, and this may limit their sensitivity to
identify potentially problematic strains. Large-scale studies are
invariably limited by sample numbers per country, and subject
to potential selection bias [5]. We requested 25 patient de-
duplicated, toxin-positive faecal samples (or C. difﬁcile iso-
lates) collected during the 12 months from July 2011 onwards,
but made no further stipulations. Participating centres were, in
the main, national or regional C. difﬁcile reference facilities.
Thus, some submissions likely included outbreak strains,
possibly inﬂuencing the data. However, the similarity of the
predominant RTs between this study and that of Bauer et al.
indicates a degree of conﬁdence [5].
It is clear that certain prevalent RTs are associated with
multiple antimicrobial resistance determinants. This study un-
derlines the association of well-known epidemic RT027 and
RT001/072 with multiple antimicrobial resistance, but also
highlights the association of other RTs with high levels of
resistance (017, 018, and 356). The potential relatedness of
RT356 and RT018 is also intriguing and requires further anal-
ysis. Similarly, the relatedness between highly resistant RT284
(rifampicin, moxiﬂoxacin, clindamycin, imipenem, and chlor-
amphenicol) and RT046 (both found in Italy) may also indicate
strain evolution concurrent with increasing antimicrobial
resistance. Geographic associations are consistent with local
antimicrobial prescribing as a selection pressure. The potential
emergence of these highly resistant RTs warrants further
monitoring and investigation, which will be undertaken as part
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